[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100615537":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":27,"centralContacts":31,"locations":37,"responsibleParty":50,"collaborators":10,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":10,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":10,"maxAge":10,"enrollmentInfo":60,"targetDuration":10,"studyType":63,"phases":10,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":40,"whyStopped":10,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Takeda","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Alagille Syndrome (ALGS) Group",null,"Participants with Alagille Syndrome (ALGS) who received maralixibat in accordance with package insert.",[13],"Drug: Maralixibat",{"label":15,"type":10,"description":16,"interventionNames":17},"Progressive Familial Intrahepatic Cholestasis (PFIC) Group","Participants with Progressive Familial Intrahepatic Cholestasis (PFIC) who received maralixibat in accordance with package insert.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Maralixibat","Maralixibat Oral Solution 10 milligrams (mg)\u002Fmilliliters (mL)",[9,15],[25,26],"TAK-625","Livmarli Oral Solution",[28],{"name":29,"affiliation":5,"role":30},"Study Director","STUDY_DIRECTOR",[32],{"name":33,"role":34,"phone":35,"phoneExt":10,"email":36},"Takeda Contact","CONTACT","+1-877-825-3327","medinfoUS@takeda.com",[38],{"facility":39,"status":40,"city":41,"state":41,"zip":10,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":10},"Takeda selected site","RECRUITING","Tokyo","Japan","JP",{"type":45,"coordinates":46},"Point",[47,48],139.69171,35.6895,{"lat":48,"lon":47},{"type":51,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100615537","a-database-study-of-maralixibat-tak-625-in-participants-with-alagille-syndrome-algs-and-progressive-familial-intrahepatic-cholestasis-pfic-100615537",false,"NCT07293897","A Database Study of Maralixibat (TAK-625) in Participants With Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC)","A Cohort Study to Investigate the Risk of Liver Disorder of Livmarli Oral Solution in Patients With Japan Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC) Registered in the Comprehensive and Informative Registry System for Childhood Liver Disease (CIRCLe)","Inclusion Criteria:\n\n* Has a diagnosis of ALGS or PFIC within the enrollment period.\n* There is a prescription for Livmarli during the enrollment period (Index date: the date of the first prescription within the enrollment period).\n\nExclusion Criteria:\n\n\\- None","ALL",{"count":61,"type":62},50,"ESTIMATED","OBSERVATIONAL","This study is a database study in Japan for maralixibat (TAK-625) used to treat participants with Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC).\n\nThe main aim of the study is to evaluate the risk of liver disorder during the use of maralixibat in Japanese patients with ALGS or PFIC.\n\nThis database study will conduct in use of medical database called Comprehensive and Informative Registry system for Childhood Liver Disease (CIRCLe).",[66,67],"Alagille Syndrome (ALGS)","Progressive Familial Intrahepatic Cholestasis (PFIC)",[66,67],"2026-02-18",{"date":71,"type":72},"2026-02-20","ACTUAL",{"date":74,"type":72},"2026-01-13",{"date":76,"type":62},"2031-06-30",{"name":5,"class":6},1]